PNV
data caveat$701MCF+
PolyNovo
Medical Devices · Wound care
NovoSorb biodegradable polymer technology for wound treatment
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$93.2M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$701M
Burn Rate
—
Dec 2025 4C
Shares Outstanding
691M
Pipeline Assets
2
Latest Insight(1)
16 Mar 2026Insider TradeChange of Director's Interest Notice - Robert Douglas
1 transaction·+$140k net buyDouglas: bought $140k
3M Price
PNV.ASX$1.015-9.0% 3M
Low $0.875High $1.115
Pipeline Assets (2)
NovoSorb MTXHernia repair
Phase 2NovoSorb BTMBurns / complex wounds
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
NovoSorb MTX
Hernia repair
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
6 transactionsLast 90dNet Buy
Buys6+6 vs prior
Sells0
Buy Value$520k
warning3 directors bought within 30 days (02-24 – 03-12) — $520k total
warningRobert Douglas bought 49d before "NovoSorb BTM US revenue growth" ($140,430)
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
14.22%
arrow_drop_up+1.91% over 30 reports
Shares short
98.2M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
17 competitor trialsPhase 2+ · Non-ASX
Hernia Repair17 active trials
7 Ph45 Ph32 Ph2/33 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
5 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Eur Burn J2025-11· NovoSorb BTM
J Burn Care Res2025-08· NovoSorb BTM
Cureus2025-07· NovoSorb BTM
Catalysts (5)· 3 upcoming · 2 past
NovoSorb BTM US revenue growth
UpcomingConfirmedremoveMed30 Apr 2026
SpeculativeremoveMed30 May 2026
NovoSorb MTX hernia trial update
UpcomingExpectedremoveMed31 Aug 2026
2 past catalysts
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High98/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — 7/7 quarters with positive operating cash flow
arrow_drop_up
Revenue growing — Customer receipts trending up
arrow_drop_up
Cash position improving — Cash balance growing
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
NAActive Not RecruitingEnrollment stale · 1674d
NovoSorb BTMStandard of Care
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
Burns
RandomizedOpen Label18 Years – 75 Years
Primary endpoint Proportion of study lesions in both groups with complete wound closure after skin grafting
Announcements(7)
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Robert Douglas16 Mar 2026
expand_more178KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Andrew Lumsden27 Feb 2026
expand_more178KB